Automera

Next generation targeted protein degradation for cancer and beyond

Harnessing computational chemistry, AI and quantum molecular dynamics to design dual-binding small molecules: Traditional therapies often target single disease components, limiting their effectiveness against complex conditions. Automera’s innovative autophagy-targeting chimeric molecules (AUTAC) platform generates novel therapies that degrade not only disease-related proteins but also protein aggregates, malfunctioning mitochondria, and pathogens, eliminating a range of disease-causing agents. AUTACs have the potential to provide a more flexible approach to protein degradation than existing approaches such as proteolysis-targeting chimeras (PROTACs) to trigger protein degradation.
Accelerating R&D with Singapore’s biotech ecosystem: Automera’s R&D is based in Singapore, leveraging the country’s efficient regulatory system, advanced biotech infrastructure, and access to diverse patient populations. This strategic location accelerates clinical trials, while Singapore’s multicultural demographic ensures inclusive recruitment, providing broad, globally relevant data that strengthens the development of Automera’s therapies for diverse patient groups.
Key Events in 2025: With an initial focus on cancer, continue advancing early pipeline assets and refining its platform.